Login
$CLNN
$3.65 -$0.01 (0.27%) After hours

$CLNN SEC Filings

Filed On Filing
13 Nov 2026 Form 4: Desai Arjun Jj, Director

Granted 3,549 stock option

13 Nov 2026 Form 4: Jacobovitz Shalom, Director

Granted 4,591 stock option

13 Nov 2026 Form 4: Mosca Alison, Director

Granted 4,707 stock option

13 Nov 2026 Form 4: Kiernan Matthew, Director

Granted 3,086 stock option

13 Nov 2026 Form 4: Matlin David J, Director

Granted 6,019 stock option

13 Nov 2026 Form 4: Gay Jonathon, Director

Granted 3,665 stock option

13 Nov 2026 Form 4: McLaughlin Vallerie, Director

Granted 3,395 stock option

13 Nov 2026 Form 4: Wilcox Reed N, Director

Granted 3,395 stock option

04 Nov 2026 FORM 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS)

21 Oct 2026 Form 4: Etherington Robert Dee, Director

Granted 55,000 stock option

21 Oct 2026 Form 4: Mortenson Mark, Chief Science Officer

Granted 30,000 stock option

21 Oct 2026 Form 4: Brown Morgan R, Chief Financial Officer

Granted 20,000 stock option

20 Oct 2026 8-K: Entry into a Material Definitive Agreement

Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS)

19 Oct 2026 8-K: Other Events

NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes

13 Oct 2026 SCHEDULE 13G/A
18 Sep 2026 Form 4: Matlin David J, Director

Received 434,451 shares as a grant or award ($1.42M)

18 Sep 2026 Form 4: Etherington Robert Dee, Director

Received 15,244 shares as a grant or award ($50K)

18 Sep 2026 Form 4: Mosca Alison, Director

Received 198,171 shares as a grant or award ($650K)

16 Sep 2026 8-K: Entry into a Material Definitive Agreement; Other Events

This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support